本文關(guān)鍵詞：血清PSA、PSAD預(yù)測前列腺癌骨轉(zhuǎn)移的臨床價值分析　出處：《新疆醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 前列腺特異性抗原 前列腺特異性抗原密度 前列腺癌 骨轉(zhuǎn)移

【摘要】：目的:探討血清前列腺特異性抗原(PSA)及前列腺特異性抗原密度(PSAD)應(yīng)用于預(yù)測前列腺癌骨轉(zhuǎn)移的臨床價值。方法:回顧性分析我院2010年1月-2016年10月經(jīng)前列腺穿刺活檢確診的前列腺癌患者63例,均行核素骨掃描檢查,根據(jù)檢查結(jié)果分為前列腺骨轉(zhuǎn)移組及前列腺癌非骨轉(zhuǎn)移組,對兩組患者的PSA及PSAD水平進(jìn)行分析,得出PSA及PSAD與前列腺癌骨轉(zhuǎn)移的關(guān)系。結(jié)果:前列腺癌骨轉(zhuǎn)移組及非骨轉(zhuǎn)移組的PSA及PSAD水平存在統(tǒng)計學(xué)差異。以PSA20ng/ml作為診斷標(biāo)準(zhǔn)預(yù)測前列腺癌骨轉(zhuǎn)移,靈敏度為89.7%,特異度為76.5%,以血清PSAD0.4ng/(ml·cm3)作為診斷標(biāo)準(zhǔn)預(yù)測前列腺癌骨轉(zhuǎn)移,靈敏度為86.2%,特異度為73.5%,兩者的ROC曲線下面積分別為0.919和0.866,以血清PSA20ng/ml聯(lián)合PSAD0.4 ng/(ml·cm3)作為標(biāo)準(zhǔn)預(yù)測臨床前列腺癌骨轉(zhuǎn)移,診斷的靈敏度為86.2%,特異度為85.3%。結(jié)論:PSA及PSAD均可應(yīng)用于前列腺癌骨轉(zhuǎn)移的預(yù)測,兩者聯(lián)合應(yīng)用可提高前列腺癌骨轉(zhuǎn)移的診斷價值,對于血清PSA20ng/ml聯(lián)合PSAD0.4ng/(ml·cm3)的患者應(yīng)高度懷疑骨轉(zhuǎn)移的存在,積極進(jìn)行骨掃描確定診斷。
[Abstract]:Objective: to study serum prostate specific antigen (PSA) and prostate specific antigen density (PSAD). Methods: 63 cases of prostate cancer diagnosed by prostate biopsy from January 2010 to 2016 were analyzed retrospectively. All patients were examined by bone radionuclide scan. According to the results, the patients were divided into two groups: bone metastasis group and non-bone metastasis group. The levels of PSA and PSAD in both groups were analyzed. The relationship between PSA and PSAD and bone metastasis of prostate cancer was obtained. The levels of PSA and PSAD in bone metastasis group and non-bone metastasis group were statistically different. PSA20ng/ml was used as diagnostic criterion to predict bone metastasis of prostate cancer. The sensitivity was 89. 7 and the specificity was 76. 5. Serum PSAD0.4ng/(ml 路cm 3 was used as diagnostic criteria for predicting bone metastasis of prostate cancer. The sensitivity was 86.2%. The specificity was 73.5 and the area under the ROC curve was 0.919 and 0.866, respectively. Serum PSA20ng/ml combined with PSAD0.4 ng/(ml 路cm 3 was used to predict bone metastasis of prostate cancer. The diagnostic sensitivity was 86.2%. Conclusion both PSAD and PSAD can be used to predict bone metastasis of prostate cancer, and the combination of them can improve the diagnostic value of bone metastasis of prostate cancer. For patients with serum PSA20ng/ml combined with PSAD0.4ng/(ml 路cm 3, bone metastasis should be highly suspected and bone scan should be actively performed to determine the diagnosis.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 翁錫君;謝立平;鄭祥義;汪朔;蔡柏森;項尖尖;尤啟漢;;前列腺特異性抗原密度預(yù)測前列腺癌包膜侵犯的價值研究[J];中國全科醫(yī)學(xué);2016年20期

2 劉銘;苗娜;朱耀;顧成元;師曉莉;崔文麗;張巍;李巧新;;Vav3基因位點多態(tài)性與中國漢族人群前列腺癌發(fā)病風(fēng)險的關(guān)聯(lián)性[J];中華病理學(xué)雜志;2016年07期

3 張志鵬;劉明;陳敏;李春媚;王鑫;王萱;萬奔;朱生才;王建業(yè);;磁共振靶向前列腺穿刺活檢對前列腺癌診斷的研究[J];中華泌尿外科雜志;2016年03期

4 王海濤;;去勢抵抗性前列腺癌精準(zhǔn)醫(yī)學(xué)研究的探索[J];中國腫瘤臨床;2015年17期

5 王野;高旭;楊慶;孫穎浩;;前列腺癌骨轉(zhuǎn)移發(fā)生機制的研究進(jìn)展[J];中華泌尿外科雜志;2015年09期

6 邵立欽;范銳;岳俊敏;�？『�;張昊;萬久愷;王朝陽;;手術(shù)去勢聯(lián)合間歇性雄激素全阻斷療法治療局部進(jìn)展期前列腺癌的療效[J];中國老年學(xué)雜志;2015年14期

7 葉楊;汪駿;秦超;華立新;;中晚期前列腺癌單藥治療與最大限度雄激素阻斷療法的療效及副作用觀察[J];現(xiàn)代泌尿外科雜志;2015年06期

8 葉定偉;朱耀;;中國前列腺癌的流行病學(xué)概述和啟示[J];中華外科雜志;2015年04期

9 錢蘇波;沈海波;曹奇峰;齊雋;;抗雄激素撤退治療去勢抵抗性前列腺癌的療效分析[J];現(xiàn)代泌尿外科雜志;2015年01期

10 沈茜剛;周良平;彭衛(wèi)軍;毛健;張靈;姚之豐;程競儀;劉曉航;丁建輝;岳磊;;背景抑制擴散加權(quán)成像與核素骨掃描在惡性腫瘤骨轉(zhuǎn)移病變診斷中的對照研究[J];中國癌癥雜志;2014年03期

，

本文編號：1407319